In this work, a method for the confirmation of synthetic opioids and related compounds was developed and evaluated.
As seized drug casework becomes increasingly complex due to the continued prevalence of emerging drugs, laboratories are often looking for new analytical approaches including developing methods for the analysis of specific compounds classes. Recent efforts have focused on the development of targeted gas chromatography mass spectrometry (GC-MS) confirmation methods to compliment the information-rich screening results produced by techniques like direct analysis in real time mass spectrometry (DART-MS). In the current project, an 11-component test solution was used to develop a method that focused on minimizing overlapping retention time acceptance windows and understanding the influence of instrument parameters on reproducibility and sensitivity. Investigated settings included column type, flow rate, temperature program, inlet temperature, source temperature, and tune type. Using a DB-200 column, a 35-min temperature ramped method was created. It was evaluated against a suite of 222 synthetic opioids and related compounds, and successfully differentiated all but four compound pairs based on nonoverlapping retention time acceptance windows or objectively different mass spectra. Compared to a general confirmatory method used in casework, the targeted method was up to 25 times more sensitive and provided at least a two-fold increase in retention time differences. Analysis of extracts from actual case samples successfully demonstrated utility of the method and showed no instance of carryover, although the high polarity column required wider retention time windows than other columns. (Publisher Abstract)
Downloads
Similar Publications
- GIS Application for Building a Nationally Representative Forensic Taphonomy Database
- Skeletal Trauma in Forensic Anthropology: Improving the Accuracy of Trauma Analysis and Expert Testimony
- In Vitro Structure-activity Relationships and Forensic Case Series of Emerging 2-benzylbenzimidazole 'Nitazene' Opioids